Several tumor vaccines against MM-associated antigens, including MAGA-C1, MUC-1, WT-1, NY-ESO-1 as well as idiotypic IgG, have been developed and combined with strategies such as dendritic cell (DC) vaccination, to be employed for immune vaccination in high-risk MM patients either alone or in combination with immune-checkpoint inhibitors [88,89]. This evidence concerns the gene MUC1 and Miyoshi myopathy.